Trial Profile

Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (Trafermin)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trafermin (Primary)
Indications Alveolar bone loss; Periodontitis
Focus Registrational; Therapeutic Use
Sponsors Kaken Pharmaceutical

Most Recent Events

01 Oct 2015 According to Kaken Pharmaceutical media release, the company submitted a new drug application (NDA) for Trafermin [KDB-1D] to the Ministry of Health, Labour and Welfare in Japan.
17 Jun 2014 New trial record
14 Jun 2010

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com